Webinar - "ADA National Network Learning Session: Global Disability Leadership Before, During and After Disasters" September 9th, 2021

 

ADA National Network: Emergency Management and Preparedness-Inclusion of Persons with Disabilities The following is provided by the Pacific ADA Center Email not displaying correctly? View it in your browser.   Announcing a New Webinar - "ADA National Network Learning Session: Global Disability Leadership Before, During and After Disasters" September 9th, 2021 Registration for this webinar is now open Webinars begin at ET: 2.30pm, CT: 1.30pm, MT:12.30pm, PT:11.30am, Hawaii: 9.30am during mainland Standard Time; 8.30am during mainland Daylight Savings Time. Registration: Free on-line at http://adapresentations.org/registrationEM.php Registration closes at midnight, September 8, 2021. All webinars offer captioning. Requests for sign language interpreters must be made the Monday before the webinar to support@adapacific.org. For all other accessibility questions about Zoom webinar conferencing software, go to https://zoom.us/accessibility. Disability leaders are very active in global disability inclusive disaster and climate initiatives. Learn about what's happening in Emergency Preparedness, Disaster Risk Reduction, Sustainable Development Goals, Climate Justice, Humanitarian Action, Community Resilience, Article 11 of the Convention on the Rights of Persons with Disabilities, Disability Inclusion Strategy, Building Back Better and other global disaster and disability initiatives. Hear an update on what Disabled Persons Organizations are working on and how to get involved. Learning objectives: Learn what disability led organizations around the world are working on in response to current disasters and planning for the ones that will surely follow. Learn how you can become more involved in these urgent and vital initiatives. Presenters: Marcie Roth Roth is the Executive Director of the World Institute on Disability and a global leader on disability and disaster. She has focused on improving outcomes for disaster-impacted people with disabilities, Disability Led Organizations and communities for 20 years. German Parodi and Shaylin Sluzalis are the Co-Directors of the Partnership for Inclusive Disaster Strategies leading in disability rights community organizing, disability-led disaster response, and empowering community resilience and optimizing outcomes for all nationwide and across the world. They have been leading The Partnership since 2019 - ensuring equal access and full inclusion before, during, and after disasters. Carlos Kaiser is the Director of ONG Inclusiva and is Global Focal Point for Inclusive Disaster Risk and Disability Management. He is also founder of the Global COVID-19 and Disability Group and the COVID-19 and Disability Group of Chile. All four speakers work closely together on global disability and disaster initiatives and they jointly cofounded the Global Alliance for Disaster Resource Acceleration in 2020 to accelerate resources to disaster impacted Disability Led Organizations where and when they are needed most.   To view upcoming sessions, go to http://adapresentations.org/scheduleEM.php To see previous sessions, go to http://www.adapresentations.org/archiveEM.php The information presented in this webinar is intended solely as informal guidance, and is neither a determination of legal rights or responsibilities by NIDILRR.

"Winter Is Coming". COVID Testing. Protect your loved ones. Vaccinations: Your right to, or not to.

BEMA International.  We don’t ask for much of our members

.

Communities at Risk (CAR)

As the only representatives of communities at risk (CAR), vulnerable populations, and communities of color globally in disaster, emergency management, and the climate risk management homeland security, and emergency management arena nationally and globally we ask that all members practice safe social distancing, protective mask protection, and obtain a vaccination against COVID-19 and its’ variants for the protection of yourself and others.

COVID-19 and Variants Testing

If you have not obtained a vaccination for the protection of your family, friends, and communities, which is your choice, obtain a COVID-19 or its variants test while ensuring you wear your protective mask, and practice safe social distancing.

Protect your family members.

Vaccinations.  A Choice

COVID-19 and its variants vaccinations are a choice.  Your choice to have, or not have a vaccination. 

Consider others in your community:  underage children, senior citizens, and other with functional needs that may not have received a vaccination for medical reason.  Ensure you practice safe procedures around them and others.

It is still your choice.

Protect your loved ones as we enter the Fall and flu season of 2021-2022.

“I care, do you?”  I trust the science.

CDS

Charles D. Sharp Chair\CEO Black Emergency Managers Association International       Cornell University Climate Fellow     Deputy Chair, Global Health Security Agenda                     Consortium            Washington, D.C.  20020 bEMA International Cooperation, Collaboration, Communication, Coordination, Community engagement, and  Partnering (C5&P)   A 501 (c) 3 organization

“Our lives are not our own. We are bound to others, past and present, and by each crime and every kindness, we birth our future.”  David Mitchell, Cloud Atlas

 

 

 

 

 

 

 

 

 

 

 

Debris Removal. New Orleans. September 7. 2021

 

Prepare for Debris Pickup Beginning on 9/7

 

 

The City of New Orleans has activated its emergency debris removal contracts to assist with storm-related cleanup. The first debris removal pass is scheduled to take place on Tuesday, Sept. 7.  Do not block roadways or place debris near trees, poles, or fire hydrants. Please follow these guidelines:

• Debris must be placed between the sidewalk and the curb for removal by the City or its contractors.  
• Avoid placement of storm debris waste under or on power lines, near trees, utility poles/boxes, fire hydrants, behind parked cars or on neutral grounds.
• Only debris resulting from Hurricane Ida is eligible for removal by the City’s emergency debris removal contractors.
• Any work done by contractors is ineligible for debris removal services by the City or its contractors.
• Commercial properties and properties serviced by private trash contracts are ineligible to receive bulk waste collection or debris removal services by the City or its contractors.
• Separate debris into the following categories:
• HOUSEHOLD GARBAGE

Bagged garbage, discarded food, paper, packaging.  (Use City issued trash cart when possible)

• CONSTRUCTION DEBRIS

Building materials, drywall, lumber, carpet, furniture, etc.

• UNBAGGED VEGETATIVE DEBRIS

Logs, leaves, tree branches, plants.

• APPLIANCES

Doors must be sealed/secured.

Curbside Solid Waste Collection 

 

Limited curbside solid waste collection resumed on Thursday, Sept. 2.  The City's solid waste contractors will only be dumping the City- issued 95-gallon trash cart during these initial passes. Residents should continue to bag their rotting waste, place in the City-issued trash cart and leave their carts on the curb until they are emptied; it will take some time for sanitation contractors to complete the full, citywide collection cycle.

 

Recycling collections have been suspended until further notice.

Some trucking businesses warn that the country’s shortage of drivers could lead to fuel shortages and higher prices at the pump

 Not even re-entry community members applying?

Training can start before release. 

Give hope before release.

Some trucking businesses warn that the country’s shortage of drivers could lead to fuel shortages and higher prices at the pump —Damian Dovarganes/AP Photo https://ewns.news/us-truck-fleets-seek-out-foreign-drivers-to-solve-labour-shortage/?amp=1 A dearth of workers willing to drive trucks has become so severe in the US that some fleet managers are petitioning to let more foreign operators into the country. Truck driving has always been a job with high turnover and a scarcity of labour. But the shortage has deepened since the pandemic, as training schools closed, some drivers quit and a stricter drug and alcohol testing system led to about 60,000 dismissals, said Bob Costello, chief economist at American Trucking Associations. The shortfall is “the worst ever”, he said. Certain smaller trucking companies are now imploring the US government to loosen or hasten visa approvals to alleviate strained supply networks. At Petroleum Marketing Group, a fuel distributor to more than 1,300 petrol stations on the US east coast, vice-president of operations André LeBlanc said he had gone “on the warpath”to warn governors, senators and the US transportation and labour departments that the lack of drivers could see fuel shortages and increased prices at the pump. He said officials could ease the situation by speeding up approval of EB-3 permanent work visas, which allow employers to bring in those “performing work for which qualified workers are not available in the US”. The scheme has an annual quota of 40,000. “I don’t think this is going to get better, but we have a solution and I’m trying to get somebody to listen to me,”LeBlanc said. Andrew Owens, chair of the board of Oregon Trucking Associations, said the idea of turning to foreign drivers was “picking up steam”. He is organising about a dozen trucking companies to meet federal lawmakers to “plead our case on just expediting EB-3s”.  Part of their pitch will be to try to get truck drivers on the US Department of Labor’s “Schedule A”list. This designation, which identifies occupations deemed to be facing a shortage of qualified individuals, could shave 10-12 months off an EB-3 process that typically takes around 18 months, said Jose Gomez-Urquiza, chief executive of Visa Solutions, which places foreign workers in the US transport industry. Another option would be to hire seasonal truck drivers on H-2B visas, which allow foreign workers to take temporary jobs that are difficult to fill domestically, Gomez-Urquiza said. Washington could ease pressure on supply chains by exempting truck drivers from the visas’60,000-person yearly quota, said Anda Malescu, managing partner at the Miami business and immigration law firm Malescu Law. It has already raised the cap on H-2B visas by 22,000 for this fiscal year. LeBlanc surmised that officials found the concept of bringing in workers unpalatable. One asked him: “You really want me to ask to try and bring in people from outside the US when we have so many people that are unemployed?”Malescu said trucking companies were most interested in drivers from Mexico and Canada, as their driving licences were recognised in the US. The US Department of Transportation said that it was “actively engaged in increasing the availability of qualified long-haul truck drivers”. Virginia-based Petroleum Marketing Group has only 26 of the 74 drivers it needs, LeBlanc said. “We’re out there recruiting and we’re not getting any bites, not even a nibble, ”he said. Additional reporting by Andrew Edgecliffe-Johnson in New York National Latino Farmers & Ranchers Trade Association 1029 Vermont Avenue, NW, Suite 601 Washington, DC 20005 Office: 202-628-8833 Email: latinofarmers@live.com Twitter: @NLFRTA www.NLFRTA.org

 

 

COVID-19 Vaccine. What are the true costs? Costs for communities at risk (CAR)? South-to-South Nations? Communities of Color?

 THE BOTTOM LINE.

1. Simply what are the per dose costs of each of the manufacturors (Pfizer, Moderna, Johnson & Johnson, others to the U.S?
2. Costs to nations in the Caribbean, Africa, Central & South America?
3. Environmental Social Governance (ESG) of each of the manufacturers globally?

Chart below is just a summary of information received.  Public requires just a simplistic view of current cost per dose.

COVID-19 Vaccine.  U.S., Great Britain, EU, Other nations

 

	U.S./dose	Great Britain	EU\dosage	Other/dosage
Pfizer		£22	€19.50	At Cost
Moderna	$25.50	$22 to $37 outside the US
Johnson & Johnson			$20.90
AstraZeneca			$2.15	over $5

Note: 

·    Moderna.

a.                 U.S. funded the development of the vaccine

b.                 Sales under the Covax vaccine initiative to low-income countries were “considerably lower than the price to the US government

·    AstraZeneca.  Pledged to provide their doses on a not-for-profit basis until the pandemic ends

·    Johnson & Johnson.  Pledged to provide their doses on a not-for-profit basis until the pandemic ends

COVID -19 Vaccine Costs. Phizer and Moderna Raise prices. August 1, 2021

https://www.ft.com/content/d415a01e-d065-44a9-bad4-f9235aa04c1a

Pfizer and Moderna raise EU Covid vaccine prices

Calls for booster shots and spread of more infectious variants underpin demand for products

Donato Paolo Mancini in Athens, Hannah Kuchler in London and Mehreen Khan in Brussels

 AUGUST 1 2021


Pfizer raised the price of its Covid-19 vaccine by more than a quarter and Moderna by more than a tenth in the latest EU supply contracts as Europe battled supply disruptions and concerns about side effects from rival products.

The groups are set to generate tens of billions of dollars in revenue this year as they sign new deals with countries anxious to secure supplies for potential booster shots in the face of the spread of the highly infectious Delta coronavirus variant. The terms of the deals, struck this year for a total of up to 2.1bn shots until 2023, were renegotiated after phase 3 trial data showed their messenger ribonucleic acid vaccines had higher efficacy rates than cheaper shots developed by Oxford/AstraZeneca and Johnson & Johnson.

The new price for a Pfizer shot was €19.50 against €15.50 previously, according to portions of the contracts seen by the Financial Times.

The price of a Moderna jab was $25.50 a dose, the contracts show, up from what people familiar with the matter said was about €19 ($22.60) in the first procurement deal but lower than a previously agreed $28.50 because the order had grown, according to one official close to the negotiations.

The official said the companies had capitalised on their market power and deployed the “usual pharma rhetoric . . . Vaccines work so they increased the ‘value’.”

Pfizer last week raised its guidance for annual vaccine revenue by nearly a third to $33.5bn, after sales of the shot helped almost double sales in the second quarter. Chief executive Albert Bourla said prices for higher-income countries were “comparable”, with middle-income countries charged about half and lower-income countries paying cost. Pfizer, which shares profits with its German partner BioNTech, expects to raise prices after the pandemic is over. The revenue gap between messenger RNA vaccines, whose genetic instructions prompt cells to make viral proteins that prime the immune system, and more traditional rivals that contain either viral proteins or an inactivated virus, is set to widen further next year according to forecasts compiled for the FT by Airfinity.

The life sciences consultancy predicts sales of Pfizer’s shot will hit $56bn with Moderna’s reaching $30bn, as they dominate the high-income markets. Sales of the AstraZeneca jab, which is priced at cost and is the largest vaccine supplied to low-income countries, are forecast to rise to $15bn next year. The EU contracts were struck at a complex moment in the bloc’s vaccine rollout, as it faced supply problems from AstraZeneca and J&J as health authorities probed a suspected link between their shots and rare blood clots. Recommended Covid-19 vaccines Covid-19 vaccine tracker: the global race to vaccinate Brussels was also battling criticism from member states led by Austria that accused the European Commission of “unfair” vaccine distribution, arguing that the EU system had left some countries short on supply.

Officials said the commission and EU governments had agreed to pay a higher price to secure proved supplies from European manufacturing plants. The new Pfizer price is the same as that agreed earlier in the year on an advance of 10m doses, officials said. One official said staff working for Moderna were especially “preposterous and arrogant” in their dealings with the commission, highlighting a lack of previous experience in government affairs.

The revenue gap between messenger RNA vaccines and more traditional rivals is set to widen further next year © Jens Schlueter/Getty Moderna, whose Covid vaccine is its first commercially approved product, did not respond to a request for comment on the details of its EU pricing but pointed to previous disclosures that smaller-volume agreements would be executed at higher prices. It reiterated that it aimed to provide effective and affordable vaccines to “all populations”.

The FT reported last year that Moderna had initially asked buyers including the EU for a price of at least high double-digit dollars per course. The commission said Brussels has reserved the right for an additional 1.8bn doses of Pfizer’s vaccine “to be ready if booster shots are necessary and should we need additional vaccines in the context of variants”.

Pfizer declined to comment on pricing, citing confidentiality.

 

 

 

Covid-19 vaccines: the contracts, prices and profits. August 11, 2021

https://www.theguardian.com/world/2021/aug/11/covid-19-vaccines-the-contracts-prices-and-profits

Raised charges and Covax deals on order books of Pfizer, BioNTech, Moderna and AstraZeneca

Wed 11 Aug 2021 12.58 EDT

Two US companies, Pfizer and Moderna, have raised the prices of their Covid-19 vaccines after data from clinical trials showed their mRNA formula was more effective than cheaper vaccines from Britain’s AstraZeneca and the American drugs maker Johnson & Johnson.

AstraZeneca and Johnson & Johnson have pledged to provide their doses on a not-for-profit basis until the pandemic ends.

Pfizer/BioNTech

Sales worth $11.3bn (£8bn) were made by Pfizer in the first half of this year from the Covid-19 jab that it developed with Germany’s BioNTech. In July it lifted its 2021 sales forecast to $33.5bn.

BioNTech expects to make revenues of nearly €16bn (£13.5bn) from the vaccine this year, as its first-half net profit jumped to almost €4bn from €142m a year earlier. 

The two firms have agreed to supply up to 1.8bn doses to the EU from December up to 2023, on top of 600m doses previously ordered this year. The US government has ordered 700m up to April next year for Americans, as well as 500m for donations to the poorest nations.

Pfizer and BioNTech are aiming to produce 3bn jabs this year and 4bn next year. They are now charging the EU €19.50 per jab, up from €15.50 in the first procurement deal, the Financial Times reported. The UK is also reportedly paying more than previously, about £22 a shot for 35m doses for next year’s autumn booster campaign.

Pfizer’s chief executive, Albert Bourla, recently explained the tiered pricing. “This means wealthier nations would pay about the cost of a takeaway meal for each dose … middle-income countries would pay roughly half that price … and to low-income countries we were offering them doses at cost.”

Moderna

This company generated nearly $6bn of sales from its Covid-19 vaccine in the first half of the year, achieving a $4bn net profit – the first half-year profit since the firm was founded in Massachusetts in 2010.

Moderna has signed $20bn worth of vaccine contracts this year, including that for 17m doses to the UK, 460m to the EU and 500m to the US. It expects to produce up to 1bn jabs this year, followed by 2bn-3bn in 2022.

It has charged the US government (which helped fund the development of the vaccine) up to $16.50 a dose, and has sold it for $22 to $37 outside the US. Last week the company also said that sales under the Covax vaccine initiative to low-income countries were “considerably lower than the price to the US government”. The firm has reportedly lifted the price it charges the EU to $25.50 a dose from about $19 in its first deal.

AstraZeneca

Revenue of $1.2bn was achieved by AstraZeneca from the vaccine it developed with the University of Oxford in the first half of the year. So far it has shipped 1bn doses globally and is aiming to produce a total of 2bn-3bn jabs this year. The UK government is in negotiations with AstraZeneca to order a new version of its vaccine adapted to tackle variants of the coronavirus. Results from clinical trials are expected later this year.

The AstraZeneca jab is the cheapest of the main Covid-19 vaccines, priced at just $2.15 a dose in the company’s contract with the EU, rising to just over $5 a shot elsewhere.

However, the EU has not ordered any more doses after the vaccine was linked with rare blood clots. AstraZeneca’s chief executive, Pascal Soriot, said last month that “at some point in the future” the company would raise its prices, adding: “We cannot be a non-profit forever, but we will never intend to make large profits.”

Novavax

Denmark has ordered 280,000 doses of Novavax’s Covid-19 vaccine for $5.8m – roughly $20.90 per dose – as part of an EU deal with the US company. The European Commission said last week it would buy up to 200m doses of the vaccine, which is yet to be approved by the EU’s drugs regulator.